Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosducin-like protein 3 (PhLP3) is a member of the phosducin-like protein family, which are small cytosolic proteins that function primarily as molecular chaperones or co-chaperones. Unlike PhLP1, PhLP3 does not play a major role in G protein signaling but instead assists the cytosolic chaperonin complex (CCT) in the folding of β-tubulin and possibly actin, thus regulating cytoskeletal dynamics[1][2][4]. PhLP3 contains a conserved thioredoxin domain and exhibits redox activity, although it does not have a canonical CXXC motif[2]. In yeast and protozoan systems, PhLP3 is essential for proper β-tubulin folding, with genetic deletion protecting cells from free β-tubulin toxicity and knockdown causing defects in microtubule architecture[1][2]. While PhLP3 is highly conserved across eukaryotes, there is limited evidence that it is a direct therapeutic target or that it plays a well-defined role in human disease[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosducin-like protein 3 (PhLP3).